First Commercial Implant of Endologix ALTO Abdominal Stent Graft System Done Outside the US by Drs. Andrew Holden and Andrew Hill

B2B Training: What’s the Most Effective Way of Learning?

B2B training, which is short for business-to-business training, is a popular and convenient type of training that enables entire companies to train their teams...

AlixPartners Forecasts: Household Products Could Cost U.S. Manufacturers and Consumers 15% More This Year Due to Resin Shortage

While companies can’t control the market forces at play, they can take action to mitigate the risk and impact of supply chain disruption.

September 2, 2020

The first commercial implant of Endologix ALTO endograft has been completed outside of the United States, by Andrew Holden, MD, and Andrew Hill, MD, of Auckland City Hospital, Auckland, New Zealand.

“With the 7 mm infrarenal placement of its sealing ring, ALTO expands the endovascular treatment of AAA patients to include short and challenging aortic necks, which represent a significant portion of the underserved AAA market,” commented Dr. Holden. “We are excited to add ALTO to our endovascular armamentarium and look forward to offering this solution to a broad set of AAA patients.”

Dr. Hill added, “The ALTO endograft, with its ultra-low-profile delivery system, is ideal for treating patients with small vessels and challenging access. The new system provides a unique endovascular option, representing an important advancement for physicians and their AAA patients.”

“We are excited to commence the global roll-out of ALTO. With our planned transition to a more agile private company and our steadfast investments in clinical evidence and innovation, we are poised to meet the needs of our customers and the patients we proudly serve. ALTO offers a unique endovascular AAA treatment option and includes design features that we believe will enhance ease-of-use, improve acute outcomes, and preserve long-term durability,” commented John Onopchenko, Chief Executive Officer of Endologix.

“With both FDA approval and CE Mark, ALTO is an important therapy for physicians and their patients and yet another example of our highly differentiated portfolio of devices aimed at addressing the current unmet needs of endovascular aneurysm repair (EVAR). As we continue to execute our strategy, Endologix is committed to investing in the highest levels of clinical evidence, by initiating a head-to-head randomized controlled trial where ALTO will be compared to traditional undifferentiated EVAR grafts, with the intent of proving the superiority of ALTO. We are passionately devoted to our patient-centric mission and its ultimate goal of improving patients’ lives by enabling a single intervention to achieve the long-term durable repair. We sincerely appreciate the support of our physician partners around the globe.”

 

 

spot_img

DON'T MISS

Mediclinic Appoints 2 New Independent Non-Executive Directors

Natalia Barsegiyan and Zarina Bassa will bring significant and diverse skills and experience, complementing those of existing Board members. I am confident they will both be great additions to our Board of Directors.”

Asensus Surgical Appoints Two New Board Members

Asensus Surgical, Inc. (NYSE American: ASXC), a medical device company that is digitizing the interface between the surgeon and the patient to pioneer a new era of Performance-Guided Surgery™, today announced the expansion of its Board of Directors, appointing...

Our Sister Publication: Biotechnology News Magazine

Subscribe to Medical Device News Magazine here.